Nuvation Bio Inc. (NYSE: NUVB) has announced it will present updated clinical data for its lead oncology candidate, IBTROZI (taletrectinib), at the AACR Annual Meeting 2026. The presentation will feature results from the pivotal TRUST-I and TRUST-II studies, focusing on patients with advanced ROS1-positive non-small cell lung cancer (NSCLC). A key highlight includes a median Duration of Response (DOR) of 50 months for patients who had not previously received TKI inhibitors. These findings underscore the potential durability and efficacy of IBTROZI in treating specific lung cancer populations. The company aims to demonstrate the long-term clinical benefits of its therapeutic approach within the competitive oncology landscape. Investors are closely watching the upcoming data release as a significant milestone for the biotech firm's development pipeline.
Sign up free to access this content
Create Free Account